- Oral 5‐aminosalicylate acid (5‐ASA) anti-inflammatory drugs are not associated with renal impairment in patients with ulcerative colitis (UC) or Crohn's disease (CD).
Why this matters
- Previous studies have offered conflicting evidence about nephrotoxicity associated with 5-ASAs.
- Researchers studied anonymised medical records of 35,601 patients with UC or CD from a large primary care database.
- Funding: Takeda Pharmaceutical Company.
- The nephrotoxicity incidence rate was similar and stable for patients with either UC (12.6 per 1000 person‐years) or CD (10.9 per 1000 person‐years).
- 5-ASA was not associated with nephrotoxicity either in patients with prescriptions ≤30 days or 31 to ≤180 days before index:
- UC: OR, 1.05 (95% CI, 0.86‐1.28).
- CD: OR, 1.22 (95% CI, 0.91‐1.62).
- Factors independently associated with renal impairment in both UC and CD included disease duration, cardiovascular disease, diabetes mellitus, and nephrotoxic drug use.
- Study data counted prescriptions issued rather than dispensed.
- The study was retrospective and did not establish causality.